• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Warby Parker Announces Third Quarter 2023 Results

    11/8/23 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email

    Net revenue increased 14.2% year over year to $169.8 million; Company raises outlook

    Average Revenue per Customer increased 10.0% year over year to $284

    Over 15 million pairs of glasses distributed through our Buy a Pair, Give a Pair program

    Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2023.

    "In Q3, we were proud to deliver our strongest revenue growth year-to-date at 14.2%," said Co-Founder and Co-CEO Neil Blumenthal. "Fueling topline results were 11 new store openings, four collection launches, contacts outperformance, and more. Customers continue to find exceptional value in our products, and we are focused on finding more ways to serve them through our growing and highly productive retail footprint, product innovation, and broader holistic vision care services."

    "As we head into the busiest time of year, our team remains laser focused on delivering remarkable experiences and value for our customers. We are confident in our strategic direction and continue to believe we are in the early innings of delivering long-term, profitable growth," added Co-Founder and Co-CEO Dave Gilboa.

    Third Quarter 2023 Highlights

    • Net revenue increased $21.1 million, or 14.2%, to $169.8 million.
    • GAAP net loss of $17.4 million.
    • Adjusted EBITDA(1) of $11.0 million and adjusted EBITDA margin(1) of 6.5%.
    • Over 15 million pairs of glasses have now been distributed to people in need through our Buy a Pair, Give a Pair program.

    Third Quarter 2023 Year Over Year Financial Results

    • Net revenue increased $21.1 million, or 14.2%, to $169.8 million.
    • Average Revenue per Customer increased 10.0% to $284. Active Customers increased 1.8% to 2.30 million.
    • Gross profit increased 9.8% to $92.7 million.
    • Gross margin was 54.6% compared to 56.7% in the prior year period. The decline in gross margin was primarily driven by the growth of contact lenses, which carry lower gross margins than our other eyewear, increased costs associated with optometrists as we scale our eye exam offering across our fleet, and increases in store occupancy costs as a percent of revenue primarily due to increased depreciation and rent charges as we grew our store base to 227 stores, up from 190 in the prior year period.
    • Selling, general and administrative expenses ("SG&A") were $112.5 million, up $4.4 million from the prior year, and represented 66.2% of revenue, down from 72.6% in the prior year period. Leverage in SG&A was primarily driven by reduced stock-based compensation costs and adjustments to our cost structure made last year, partially offset by increased marketing costs and technology costs. Adjusted SG&A(1) was $93.4 million, or 55.0% of revenue, versus $82.3 million, or 55.3% of revenue in the prior year period.
    • GAAP net loss improved $6.4 million to $17.4 million, primarily as a result of the increase in revenue described above.
    • Adjusted EBITDA(1) decreased $0.9 million to $11.0 million and adjusted EBITDA margin(1) decreased 1.5 points to 6.5%.
    • Opened 11 new stores during the quarter, ending Q3 with 227 stores.

    Balance Sheet Highlights

    Warby Parker ended the third quarter of 2023 with $216.0 million in cash and cash equivalents.

    2023 Outlook

    For the full year 2023, Warby Parker is revising guidance to be as follows:

    • Net revenue of $666 to $669 million, representing growth of approximately 11.5% at the midpoint versus full year 2022.
    • Adjusted EBITDA(1) of approximately $52.7 million, or adjusted EBITDA margin(1) of 7.9%.
    • On track for 40 new store openings this year.

    "While both our top and bottom line exceeded our prior outlook for the third quarter, we are cognizant of headwinds facing the consumer in the current macro environment," said Chief Financial Officer Steve Miller. "Given our outperformance year-to-date, we are raising our full year revenue guidance and maintaining a disciplined approach to spend."

    The guidance and forward-looking statements made in this press release and on our conference call are based on management's expectations as of the date of this press release.

    (1) Please see the reconciliation of non-GAAP financial measures to the most comparable GAAP financial measure in the section titled "Non-GAAP Financial Measures" below.

    Webcast and Conference Call

    A conference call to discuss Warby Parker's third quarter 2023 results, as well as fourth quarter and full year 2023 outlook, is scheduled for 8:00 a.m. ET today. To participate, please dial 833-470-1428 from the U.S. or 646-904-5544 from international locations. The conference passcode is 323975. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where presentation materials will also be posted prior to the conference call. A replay will be made available online approximately two hours following the live call for a period of 90 days.

    Forward-Looking Statements

    This press release and the related conference call, webcast and presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, expectations of future operating results or financial performance, including expectations regarding achieving profitability and growth in our e-commerce channel, delivering stakeholder value, growing market share, and our guidance for the quarter and year ending December 31, 2023; expectations regarding the number of new store openings during the year ending December 31, 2023; management's plans, priorities, initiatives and strategies; and expectations regarding growth of our business. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "toward," "will," or "would," or the negative of these words or other similar terms or expressions. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all.

    Forward-looking statements are based on information available at the time those statements are made and are based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control, that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. These risks and uncertainties include our ability to manage our future growth effectively; our expectations regarding cost of goods sold, gross margin, channel mix, customer mix, and selling, general, and administrative expenses; increases in component and shipping costs and changes in supply chain; our reliance on our information technology systems and enterprise resource planning systems for our business to effectively operate and safeguard confidential information; our ability to engage our existing customers and obtain new customers; planned new retail stores in 2023 and going forward; an overall decline in the health of the economy and other factors impacting consumer spending, such as recessionary conditions, inflation, government instability, and geopolitical unrest; our ability to compete successfully; our ability to manage our inventory balances and shrinkage; the growth of our brand awareness; our ability to recruit and retain optometrists, opticians, and other vision care professionals; a resurgence of COVID-19 or the spread of new infectious diseases; the effects of seasonal trends on our results of operations; our ability to stay in compliance with extensive laws and regulations that apply to our business and operations; our ability to adequately maintain and protect our intellectual property and proprietary rights; our reliance on third parties for our products, operation and infrastructure; our duties related to being a public benefit corporation; the ability of our Co-Founders and Co-CEOs to exercise significant influence over all matters submitted to stockholders for approval; the effect of our multi-class structure on the trading price of our Class A common stock; and the increased expenses associated with being a public company. Additional information regarding these and other risks and uncertainties that could cause actual results to differ materially from the Company's expectations is included in our most recent reports filed with the SEC on Form 10-K and Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

    Additional information regarding these and other factors that could affect the Company's results is included in the Company's SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.

    Glossary

    Active Customer is defined as a unique customer that has made at least one purchase of any product or service in the preceding 12-month period.

    Average Revenue per Customer is defined as net revenue for a given period divided by the number of Active Customers as of the end of that same period.

    Non-GAAP Financial Measures

    We use adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted earnings per share, adjusted cost of goods sold ("adjusted COGS"), adjusted gross margin, adjusted gross profit, and adjusted selling, general, and administrative expenses ("adjusted SG&A") as important indicators of our operating performance. Collectively, we refer to these non-GAAP financial measures as our "Non-GAAP Measures." The Non-GAAP Measures, when taken collectively with our GAAP results, may be helpful to investors because they provide consistency and comparability with past financial performance and assist in comparisons with other companies, some of which use similar non-GAAP financial information to supplement their GAAP results.

    Adjusted EBITDA is defined as net income (loss) before interest and other income, taxes, and depreciation and amortization as further adjusted for asset impairment costs, stock-based compensation expense and related employer payroll taxes, amortization of cloud-based software implementation costs, non-cash charitable donations, and non-recurring costs such as major system implementation costs and restructuring costs. Adjusted EBITDA margin is defined as adjusted EBITDA divided by net revenue.

    Adjusted net income (loss) is defined as net income (loss) adjusted for stock-based compensation expense and related employer payroll taxes, non-cash charitable donations, and non-recurring costs such as major system implementation costs and restructuring costs, and as further adjusted for estimated income tax on such adjusted items.

    Adjusted earnings (loss) per share is defined as adjusted net income (loss) divided by adjusted weighted average shares outstanding.

    Adjusted COGS is defined as cost of goods sold adjusted for stock-based compensation expense and related employer payroll taxes.

    Adjusted gross profit is defined as net revenue minus adjusted COGS. Adjusted gross margin is defined as adjusted gross profit divided by net revenue.

    Adjusted SG&A is defined as SG&A adjusted for stock-based compensation expense and related employer payroll taxes, non-cash charitable donations, and non-recurring costs such as major system implementation costs and restructuring costs.

    The Non-GAAP Measures are presented for supplemental informational purposes only. A reconciliation of historical GAAP to Non-GAAP financial information is included under "Selected Financial Information" below.

    We have not reconciled our adjusted EBITDA margin guidance to GAAP net income (loss) margin, or net margin, or adjusted EBITDA guidance to GAAP net income (loss) because we do not provide guidance for GAAP net margin or GAAP net income (loss) due to the uncertainty and potential variability of stock-based compensation and taxes, which are reconciling items between GAAP net margin and adjusted EBITDA margin and GAAP net income (loss) and adjusted EBITDA, respectively. Because such items cannot be reasonably provided without unreasonable efforts, we are unable to provide a reconciliation of the adjusted EBITDA margin guidance to GAAP net margin and adjusted EBITDA guidance to GAAP net income (loss). However, such items could have a significant impact on GAAP net margin and GAAP net income (loss).

    About Warby Parker

    Warby Parker (NYSE:WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City, the co-founder-led lifestyle brand pioneers ideas, designs products, and develops technologies that help people see, from designer-quality prescription glasses (starting at $95) and contacts, to eye exams and vision tests available online and in more than 200 retail stores across the U.S. and Canada.

    Warby Parker aims to demonstrate that businesses can scale, do well, and do good in the world. Ultimately, the brand believes in vision for all, which is why for every pair of glasses or sunglasses sold, they distribute a pair to someone in need through their Buy a Pair, Give a Pair program. To date, Warby Parker has worked alongside its nonprofit partners to distribute more than 15 million glasses to people in need.

    Selected Financial Information

    Warby Parker Inc. and Subsidiaries

    Consolidated Balance Sheets (Unaudited)

    (Amounts in thousands, except share data)

     

     

    September 30, 2023

     

    December 31, 2022

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    215,965

     

     

    $

    208,585

     

    Accounts receivable, net

     

    721

     

     

     

    1,435

     

    Inventory

     

    63,617

     

     

     

    68,848

     

    Prepaid expenses and other current assets

     

    15,179

     

     

     

    15,700

     

    Total current assets

     

    295,482

     

     

     

    294,568

     

     

     

     

     

    Property and equipment, net

     

    151,109

     

     

     

    138,628

     

    Right-of-use lease assets

     

    120,359

     

     

     

    127,014

     

    Other assets

     

    7,929

     

     

     

    8,497

     

    Total assets

    $

    574,879

     

     

    $

    568,707

     

     

     

     

     

    Liabilities and Stockholders' Equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    24,207

     

     

    $

    20,791

     

    Accrued expenses

     

    54,640

     

     

     

    58,222

     

    Deferred revenue

     

    17,623

     

     

     

    25,628

     

    Current lease liabilities

     

    23,086

     

     

     

    22,546

     

    Other current liabilities

     

    2,254

     

     

     

    2,370

     

    Total current liabilities

     

    121,810

     

     

     

    129,557

     

     

     

     

     

    Non-current lease liabilities

     

    147,096

     

     

     

    150,832

     

    Other liabilities

     

    1,362

     

     

     

    1,672

     

    Total liabilities

     

    270,268

     

     

     

    282,061

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock, $0.0001 par value; Class A: 750,000,000 shares authorized at September 30, 2023 and December 31, 2022, 97,779,105 and 96,115,202 issued and outstanding at September 30, 2023 and December 31, 2022, respectively; Class B: 150,000,000 shares authorized at September 30, 2023 and December 31, 2022, 19,479,598 and 19,223,572 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively, convertible to Class A on a one-to-one basis

     

    12

     

     

     

    12

     

    Additional paid-in capital

     

    954,019

     

     

     

    890,915

     

    Accumulated deficit

     

    (647,784

    )

     

     

    (603,634

    )

    Accumulated other comprehensive loss

     

    (1,636

    )

     

     

    (647

    )

    Total stockholders' equity

     

    304,611

     

     

     

    286,646

     

    Total liabilities and stockholders' equity

    $

    574,879

     

     

    $

    568,707

     

     

    Warby Parker Inc. and Subsidiaries

    Consolidated Statements of Operations (Unaudited)

    (Amounts in thousands, except share and per share data)

     

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Net revenue

    $

    169,849

     

     

    $

    148,777

     

     

    $

    507,910

     

     

    $

    451,619

     

    Cost of goods sold

     

    77,117

     

    64,359

     

    229,752

     

     

     

    191,208

     

    Gross profit

     

    92,732

     

     

     

    84,418

     

     

     

    278,158

     

     

     

    260,411

     

     

     

     

     

     

     

     

     

    Selling, general, and administrative expenses

     

    112,499

     

     

     

    108,090

     

     

     

    328,585

     

     

     

    349,904

     

    Loss from operations

     

    (19,767

    )

     

     

    (23,672

    )

     

     

    (50,427

    )

     

     

    (89,493

    )

     

     

     

     

     

     

     

     

    Interest and other income (loss), net

     

    2,655

     

     

     

    (183

    )

     

     

    6,815

     

     

     

    (75

    )

     

     

     

     

     

     

     

     

    Loss before income taxes

     

    (17,112

    )

     

     

    (23,855

    )

     

     

    (43,612

    )

     

     

    (89,568

    )

    Provision for income taxes

     

    301

     

     

     

    (12

    )

     

     

    538

     

     

     

    574

     

    Net loss

    $

    (17,413

    )

     

    $

    (23,843

    )

     

    $

    (44,150

    )

     

    $

    (90,142

    )

     

     

     

     

     

     

     

     

    Net loss per share attributable to common stockholders, basic and diluted

    $

    (0.15

    )

     

    $

    (0.21

    )

     

    $

    (0.38

    )

     

    $

    (0.79

    )

    Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted

     

    118,003,640

     

     

     

    115,249,431

     

     

     

    116,995,545

     

     

     

    114,681,893

     

       

    Warby Parker Inc. and Subsidiaries

    Consolidated Statements of Cash Flows (Unaudited)

    (Amounts in thousands)

       

     

    Nine Months Ended September 30,

     

     

    2023

     

     

     

    2022

     

    Cash flows from operating activities

     

     

     

     

    Net loss

    $

    (44,150

    )

     

    $

    (90,142

    )

    Adjustments to reconcile net loss to net cash provided by operating activities:

     

     

     

     

    Depreciation and amortization

     

    28,184

     

     

     

    22,947

     

    Stock-based compensation

     

    54,083

     

     

     

    78,209

     

    Non-cash charitable contribution

     

    3,191

     

     

     

    3,270

     

    Asset impairment charges

     

    1,407

     

     

     

    1,509

     

    Amortization of cloud-based software implementation costs

     

    1,679

     

     

     

    96

     

    Change in operating assets and liabilities:

     

     

     

     

    Accounts receivable, net

     

    714

     

     

     

    (126

    )

    Inventory

     

    5,231

     

     

     

    (13,522

    )

    Prepaid expenses and other assets

     

    410

     

     

     

    (4,546

    )

    Accounts payable

     

    2,756

     

     

     

    (9,209

    )

    Accrued expenses

     

    (1,207

    )

     

     

    (4,319

    )

    Deferred revenue

     

    (8,005

    )

     

     

    (5,796

    )

    Other current liabilities

     

    (116

    )

     

     

    (6

    )

    Right-of-use lease assets and current and non-current lease liabilities

     

    3,458

     

     

     

    6,346

     

    Other liabilities

     

    (309

    )

     

     

    1,820

     

    Net cash provided by (used in) operating activities

     

    47,326

     

     

     

    (13,469

    )

    Cash flows from investing activities

     

     

     

     

    Purchases of property and equipment

     

    (40,098

    )

     

     

    (45,966

    )

    Investment in optical equipment company

     

    (1,000

    )

     

     

    —

     

    Net cash used in investing activities

     

    (41,098

    )

     

     

    (45,966

    )

    Cash flows from financing activities

     

     

     

     

    Proceeds from stock option exercises

     

    1,017

     

     

     

    295

     

    Proceeds from shares issued in connection with employee stock purchase plan

     

    1,124

     

     

     

    1,754

     

    Proceeds from repayment of related party loans

    —

     

     

     

    45

     

    Net cash provided by financing activities

     

    2,141

     

     

     

    2,094

     

    Effect of exchange rates on cash

     

    (989

    )

     

     

    (1,190

    )

    Net change in cash and cash equivalents

     

    7,380

     

     

     

    (58,531

    )

    Cash and cash equivalents, beginning of period

     

    208,585

     

     

     

    256,416

     

    Cash and cash equivalents, end of period

    $

    215,965

     

     

    $

    197,885

     

    Supplemental disclosures

     

     

     

     

    Cash paid for income taxes

    $

    400

     

     

    $

    471

     

    Cash paid for interest

     

    155

     

     

     

    89

     

    Cash paid for amounts included in the measurement of lease liabilities

     

    27,124

     

     

     

    23,262

     

    Non-cash investing and financing activities:

     

     

     

     

    Purchases of property and equipment included in accounts payable and accrued expenses

    $

    5,941

     

     

    $

    4,819

     

    Warby Parker Inc. and Subsidiaries

    Reconciliation of GAAP to Non-GAAP Measures (Unaudited)

    The following table reconciles adjusted EBITDA and adjusted EBITDA margin to the most directly comparable GAAP measure, which is net loss:

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    unaudited (in thousands)

     

    unaudited (in thousands)

    Net loss

    $

    (17,413

    )

     

    $

    (23,843

    )

     

    $

    (44,150

    )

     

    $

    (90,142

    )

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Interest and other income (loss), net

     

    (2,655

    )

     

     

    183

     

     

     

    (6,815

    )

     

     

    75

     

    Provision for income taxes

     

    301

     

     

     

    (12

    )

     

     

    538

     

     

     

    574

     

    Depreciation and amortization expense

     

    9,760

     

     

     

    8,342

     

     

     

    28,184

     

     

     

    22,947

     

    Asset impairment charges

     

    757

     

     

     

    1,097

     

     

     

    1,407

     

     

     

    1,509

     

    Stock-based compensation expense(1)

     

    16,466

     

     

     

    24,358

     

     

     

    54,496

     

     

     

    78,603

     

    Non-cash charitable donation(2)

     

    2,591

     

     

     

    —

     

     

     

    3,191

     

     

     

    3,270

     

    Amortization of cloud-based software implementation costs(3)

     

    853

     

     

     

    96

     

     

     

    1,679

     

     

     

    96

     

    ERP implementation costs(4)

     

    371

     

     

     

    170

     

     

     

    4,413

     

     

     

    170

     

    Restructuring costs(5)

     

    —

     

     

     

    1,535

     

     

     

    —

     

     

     

    1,535

     

    Adjusted EBITDA

     

    11,031

     

     

     

    11,926

     

     

     

    42,943

     

     

     

    18,637

     

    Adjusted EBITDA margin

     

    6.5

    %

     

     

    8.0

    %

     

     

    8.5

    %

     

     

    4.1

    %

    (1)

    Represents expenses related to the Company's equity-based compensation programs and related employer payroll taxes, which may vary significantly from period to period depending upon various factors including the timing, number, and the valuation of awards granted, and vesting of awards including the satisfaction of performance conditions. For the three months ended September 30, 2023 and 2022, the amount includes $0.2 million and $0.1 million, respectively, of employer payroll costs associated with releases of RSUs and option exercises. For both the nine months ended September 30, 2023 and 2022, the amount includes $0.4 million of employer payroll costs associated with releases of RSUs and option exercises.

    (2)

    Represents charitable expense recorded in connection with the donation of 56,938 shares of Class A common stock to charitable donor advised funds in June 2023 and 178,572 shares of Class A common stock in both August 2023 and May 2022 to the Warby Parker Impact Foundation.

    (3)

    Represents the amortization of costs capitalized in connection with the implementation of cloud-based software.

    (4)

    Represents internal and external non-capitalized costs related to the implementation of our new Enterprise Resource Planning ("ERP") system.

    (5)

    Represents employee severance and related costs for our restructuring plan that was executed in August 2022.

    Warby Parker Inc. and Subsidiaries

    Reconciliation of GAAP to Non-GAAP Measures (Unaudited)

    The following table presents our non-GAAP, or adjusted, financial measures for the periods presented as a percentage of revenue. Each cost and operating expense is adjusted for stock-based compensation expense and related employer payroll taxes and ERP implementation costs, if applicable.

     

    Reported

     

    Adjusted

     

    Reported

     

    Adjusted

     

    Three Months Ended September 30,

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

    Nine Months Ended September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (unaudited, in thousands)

     

    (unaudited, in thousands)

     

    (unaudited, in thousands)

     

    (unaudited, in thousands)

    Cost of goods sold

    $

    77,117

     

     

    $

    64,359

     

     

    $

    76,835

     

     

    $

    64,120

     

     

    $

    229,752

     

     

    $

    191,208

     

     

    $

    228,976

     

     

    $

    190,499

     

    % of Revenue

     

    45.4

    %

     

     

    43.3

    %

     

     

    45.2

    %

     

     

    43.1

    %

     

     

    45.2

    %

     

     

    42.3

    %

     

     

    45.1

    %

     

     

    42.2

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross profit

    $

    92,732

     

     

    $

    84,418

     

     

    $

    93,014

     

     

    $

    84,657

     

     

    $

    278,158

     

     

    $

    260,411

     

     

    $

    278,934

     

     

    $

    261,120

     

    % of Revenue

     

    54.6

    %

     

     

    56.7

    %

     

     

    54.8

    %

     

     

    56.9

    %

     

     

    54.8

    %

     

     

    57.7

    %

     

     

    54.9

    %

     

     

    57.8

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Selling, general, and administrative expenses

    $

    112,499

     

     

    $

    108,090

     

     

    $

    93,353

     

     

    $

    82,266

     

     

    $

    328,585

     

     

    $

    349,904

     

     

    $

    267,261

     

     

    $

    267,035

     

    % of Revenue

     

    66.2

    %

     

     

    72.6

    %

     

     

    55.0

    %

     

     

    55.3

    %

     

     

    64.7

    %

     

     

    77.5

    %

     

     

    52.6

    %

     

     

    59.1

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net (loss) income

    $

    (17,413

    )

     

    $

    (23,843

    )

     

    $

    1,634

     

     

    $

    1,558

     

     

    $

    (44,150

    )

     

    $

    (90,142

    )

     

    $

    13,041

     

     

    $

    (4,225

    )

    % of Revenue

     

    (10.3

    )%

     

     

    (16.0

    )%

     

     

    1.0

    %

     

     

    1.0

    %

     

     

    (8.7

    )%

     

     

    (20.0

    )%

     

     

    2.6

    %

     

     

    (0.9

    )%

    Warby Parker Inc. and Subsidiaries

    Reconciliation of GAAP to Non-GAAP Measures (Unaudited)

    The following table reflects a reconciliation of each non-GAAP, or adjusted, financial measure to its most directly comparable financial measure prepared in accordance with GAAP:

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (unaudited, in thousands)

     

    (unaudited, in thousands)

    Cost of goods sold

    $

    77,117

     

     

    $

    64,359

     

     

    $

    229,752

     

     

    $

    191,208

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation expense(1)

     

    282

     

     

     

    239

     

     

     

    776

     

     

     

    709

     

    Adjusted cost of goods sold

    $

    76,835

     

     

    $

    64,120

     

     

    $

    228,976

     

     

    $

    190,499

     

     

     

     

     

     

     

     

     

    Gross profit

    $

    92,732

     

     

    $

    84,418

     

     

    $

    278,158

     

     

    $

    260,411

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation expense(1)

     

    282

     

     

     

    239

     

     

     

    776

     

     

     

    709

     

    Adjusted gross profit

    $

    93,014

     

     

    $

    84,657

     

     

    $

    278,934

     

     

    $

    261,120

     

     

     

     

     

     

     

     

     

    Selling, general, and administrative expenses

    $

    112,499

     

     

    $

    108,090

     

     

    $

    328,585

     

     

    $

    349,904

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation expense(1)

     

    16,184

     

     

     

    24,119

     

     

     

    53,720

     

     

     

    77,894

     

    Non-cash charitable donation(2)

     

    2,591

     

     

     

    —

     

     

     

    3,191

     

     

     

    3,270

     

    ERP implementation costs(3)

     

    371

     

     

     

    170

     

     

     

    4,413

     

     

     

    170

     

    Restructuring costs(4)

     

    —

     

     

     

    1,535

     

     

     

    —

     

     

     

    1,535

     

    Adjusted selling, general, and administrative expenses

    $

    93,353

     

     

    $

    82,266

     

     

    $

    267,261

     

     

    $

    267,035

     

     

     

     

     

     

     

     

     

    Net loss

    $

    (17,413

    )

     

    $

    (23,843

    )

     

    $

    (44,150

    )

     

    $

    (90,142

    )

    Provision for income taxes

     

    301

     

     

     

    (12

    )

     

     

    538

     

     

     

    574

     

    Loss before income taxes

     

    (17,112

    )

     

     

    (23,855

    )

     

     

    (43,612

    )

     

     

    (89,568

    )

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Stock-based compensation expense(1)

     

    16,466

     

     

     

    24,358

     

     

     

    54,496

     

     

     

    78,603

     

    Non-cash charitable donation(2)

     

    2,591

     

     

     

    —

     

     

     

    3,191

     

     

     

    3,270

     

    ERP implementation costs(3)

     

    371

     

     

     

    170

     

     

     

    4,413

     

     

     

    170

     

    Restructuring costs(4)

     

    —

     

     

     

    1,535

     

     

     

    —

     

     

     

    1,535

     

    Adjusted provision for income taxes(5)

     

    (682

    )

     

     

    (650

    )

     

     

    (5,447

    )

     

     

    1,765

     

    Adjusted net income (loss)

    $

    1,634

     

     

    $

    1,558

     

     

    $

    13,041

     

     

    $

    (4,225

    )

     

     

     

     

     

     

     

     

    Adjusted weighted average shares - diluted

     

    118,617,828

     

     

     

    115,844,962

     

     

     

    117,855,800

     

     

     

    114,681,893

     

    Adjusted diluted earnings (loss) per share

    $

    0.01

     

     

    $

    0.01

     

     

    $

    0.11

     

     

    $

    (0.04

    )

    (1)

    Represents expenses related to the Company's equity-based compensation programs and related employer payroll taxes, which may vary significantly from period to period depending upon various factors including the timing, number, and the valuation of awards granted, and vesting of awards including the satisfaction of performance conditions. For the three months ended September 30, 2023 and 2022, the amount includes $0.2 million and $0.1 million, respectively, of employer payroll costs associated with releases of RSUs and option exercises. For both the nine months ended September 30, 2023 and 2022, the amount includes $0.4 million of employer payroll costs associated with releases of RSUs and option exercises.

    (2)

    Represents charitable expense recorded in connection with the donation of 56,938 shares of Class A common stock to charitable donor advised funds in June 2023 and 178,572 shares of Class A common stock in both August 2023 and May 2022 to the Warby Parker Impact Foundation.

    (3)

    Represents internal and external non-capitalized costs related to the implementation of our new ERP system.

    (4)

    Represents employee severance and related costs for our restructuring plan that was executed in August 2022.

    (5)

    The adjusted provision for income taxes is based on long-term estimated annual effective tax rate 29.46% in both 2023 and 2022. The Company may adjust its adjusted tax rate as additional information becomes available or events occur which may materially affect this rate, including impacts from the rapidly evolving global tax environment, significant changes in our geographic mix, merger and acquisition activity, or changes in our business outlook.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231108562093/en/

    Get the next $WRBY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    12/10/2025$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    11/7/2025$28.00 → $24.00Outperform
    Telsey Advisory Group
    8/1/2025$22.00 → $28.00Outperform
    Telsey Advisory Group
    7/10/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    More analyst ratings

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Mitchell Adrian V

    4 - Warby Parker Inc. (0001504776) (Issuer)

    2/12/26 7:01:12 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Mitchell Adrian V

    3 - Warby Parker Inc. (0001504776) (Issuer)

    2/12/26 6:59:22 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Blumenthal Neil Harris sold $19,793 worth of shares (660 units at $29.99) and converted options into 660 shares (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    1/15/26 6:36:33 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Warby Parker upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Warby Parker from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    12/10/25 9:45:30 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $24.00 from $28.00 previously

    11/7/25 7:48:31 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $28.00 from $22.00 previously

    8/1/25 8:16:04 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Warby Parker to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2025 will be released before market open on February 26, 2026. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 275034. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.c

    2/12/26 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Appoints Adrian Mitchell as Chief Financial Officer

    Warby Parker Inc. (NYSE:WRBY), a direct-to-consumer lifestyle brand focused on vision for all, today announced the appointment of Adrian Mitchell as Chief Financial Officer, effective February 10, 2026. His appointment strengthens Warby Parker's leadership team as the company continues executing its strategic vision, building on a track record of retail and product innovation while expanding into new categories, including the launch of its first AI glasses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209259218/en/Adrian Mitchell, Chief Financial Officer Mitchell has more than 25 years of experience leading some of the worl

    2/9/26 4:10:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

    Warby Parker Inc. (NYSE: WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2, 2025 at 3:00 p.m. Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com. An online archive will be available for a period of 90 days following the presentation. About Warby Parker Warby Parker (NYSE:WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City, the co-

    11/26/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    SEC Filings

    View All

    Warby Parker Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Warby Parker Inc. (0001504776) (Filer)

    2/9/26 4:19:28 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Warby Parker Inc.

    SCHEDULE 13G/A - Warby Parker Inc. (0001504776) (Subject)

    1/23/26 11:08:18 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    SEC Form 144 filed by Warby Parker Inc.

    144 - Warby Parker Inc. (0001504776) (Subject)

    1/13/26 4:21:45 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    8/14/24 4:52:02 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Financials

    Live finance-specific insights

    View All

    Warby Parker to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2025 will be released before market open on February 26, 2026. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 275034. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.c

    2/12/26 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Third Quarter 2025 Results

    Net revenue growth accelerated to 15% year over year Active Customers growth accelerated to 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. "This was a strong quarter for our team as we advanced our strategic priorities and accelerated both topline and customer growth. As we step into Warby Parker's next act, one defined by innovation through AI, we're energized to create new products like AI glasses, enhance the customer experience and drive productivity," shared Co-Founder and Co-CEO Neil Blume

    11/6/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker to Announce Third Quarter 2025 Financial Results November 6, 2025

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2025 will be released before market open on November 6, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 958403. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where p

    10/16/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Leadership Updates

    Live Leadership Updates

    View All

    Warby Parker Appoints Adrian Mitchell as Chief Financial Officer

    Warby Parker Inc. (NYSE:WRBY), a direct-to-consumer lifestyle brand focused on vision for all, today announced the appointment of Adrian Mitchell as Chief Financial Officer, effective February 10, 2026. His appointment strengthens Warby Parker's leadership team as the company continues executing its strategic vision, building on a track record of retail and product innovation while expanding into new categories, including the launch of its first AI glasses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209259218/en/Adrian Mitchell, Chief Financial Officer Mitchell has more than 25 years of experience leading some of the worl

    2/9/26 4:10:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Monumental Sports & Entertainment Appoints Corporate Finance Executive Steven Miller as Executive Vice President and Chief Financial Officer

    Steven Miller, currently Chief Financial Officer and Treasurer of Warby Parker (NYSE: WRBY), has been appointed Chief Financial Officer of Monumental Sports & Entertainment, effective October 2, 2025, and will join the Senior Executive Leadership TeamAs previously announced, after an extraordinary 25-year career at Monumental Sports & Entertainment, Peter Biché transitioned from Chief Financial Officer to Senior Advisor WASHINGTON, Sept. 9, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE), one of the nation's leading integrated sports, media, and entertainment companies, announced that Steven (Steve) Miller will become its Executive Vice President and Chief Financial Officer (CFO

    9/9/25 6:30:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

    Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

    8/1/24 4:15:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 5:08:23 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 1:30:16 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/12/24 10:40:28 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care